Subtype
Malignant Reproductive System Neoplasm
CI-CAN-00001172Explore in graph →
2,809 active trials38 approved drugs186 evidence items
- NCIt
- C36076
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001172Explore in graph →
Clinical trials
12,163 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,473)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01881867 | CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 2 | 54 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 9, 2019 | clinicaltrials |
| NCT01006395 | Prevention of Micro-architectural Bone Decay in Males With Non-metastatic Prostate Cancer Receiving Androgen Deprivation Therapy (ADT) | completed | Phase 2 / Phase 3 | 64 | Austin HealthOTHER_GOV | 1 | Jul 5, 2019 | clinicaltrials |
| NCT01094132 | Combined Digital Colposcopy Analysis to Improve Cervical Precancer and Cancer Detection(MDC_Algo) | completed | Phase 2 | 551 | British Columbia Cancer AgencyOTHER | 2 | Jul 5, 2019 | clinicaltrials |
| NCT01543776 | Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer | completed | Phase 2 | 72 | University of ChicagoOTHER | 2 | Jul 5, 2019 | clinicaltrials |
| NCT01867710 | Abiraterone With Different Steroid Regimens for Side Effect Related to Mineralcorticoid Excess Prevention in Prostate Cancer Prior to Chemotherapy | completed | Phase 2 | 164 | Janssen Pharmaceutica N.V., BelgiumINDUSTRY | 4 | Jul 5, 2019 | clinicaltrials |
| NCT01567891 | CT Antigen TCR-redirected T Cells for Ovarian Cancer. | completed | Phase 1 / Phase 2 | 9 | AdaptimmuneINDUSTRY | 1 | Jun 27, 2019 | clinicaltrials |
| NCT00003259 | Vinorelbine in Treating Patients With Metastatic Prostate Cancer | completed | Phase 2 | 40 | Swiss Cancer InstituteOTHER | 1 | Jun 26, 2019 | clinicaltrials |
| NCT00006023 | Capecitabine in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy | completed | Phase 2 | — | Swiss Cancer InstituteOTHER | 1 | Jun 26, 2019 | clinicaltrials |
| NCT02057939 | Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM)(STREAM) | completed | Phase 2 | 38 | Duke UniversityOTHER | 1 | Jun 26, 2019 | clinicaltrials |
| NCT02323646 | Safety and Efficacy of Telapristone Acetate (Proellex®) Administered Vaginally for the Treatment of Uterine Fibroids | completed | Phase 2 | 42 | Repros Therapeutics Inc.INDUSTRY | 1 | Jun 25, 2019 | clinicaltrials |
| NCT00958334 | Extension Study of Proellex in Women Who Have Previously Completed Study ZPU 003 | completed | Phase 2 | 65 | Repros Therapeutics Inc.INDUSTRY | 1 | Jun 18, 2019 | clinicaltrials |
| NCT01026623 | Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer | completed | Phase 1 / Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | Jun 17, 2019 | clinicaltrials |
| NCT00826150 | Phase 1/2a Study of DTA-H19 in Advanced Stage Ovarian Cancer | completed | Phase 1 / Phase 2 | 14 | Anchiano Therapeutics Israel Ltd.INDUSTRY | 1 | Jun 13, 2019 | clinicaltrials |
| NCT02467907 | Safety and Efficacy of Bevacizumab in Combination With Carboplatin and Paclitaxel for Metastatic, Recurrent or Persistent Cervical Cancer | completed | Phase 2 | 152 | Hoffmann-La RocheINDUSTRY | 18 | Jun 3, 2019 | clinicaltrials |
| NCT01289041 | BKM120 as Second-line Therapy for Advanced Endometrial Cancer | completed | Phase 2 | 70 | Novartis PharmaceuticalsINDUSTRY | 13 | May 30, 2019 | clinicaltrials |
| NCT01610869 | Low Dose Cyclophosphamide +/-- Nintedanib in Advanced Ovarian Cancer(METRO-BIBF) | completed | Phase 2 | 117 | University College, LondonOTHER | 1 | May 29, 2019 | clinicaltrials |
| NCT03543670 | Evaluation of Oncoxin-Viusid® in Prostate Cancer | completed | Phase 2 | 25 | Catalysis SLINDUSTRY | 1 | May 22, 2019 | clinicaltrials |
| NCT00728663 | Docetaxel and Cetuximab in Treating Patients With Metastatic Prostate Cancer | completed | Phase 2 | 35 | Swiss Cancer InstituteOTHER | 1 | May 14, 2019 | clinicaltrials |
| NCT01556841 | The Activity of TroVax® Versus Placebo in Relapsed Asymptomatic Ovarian Cancer(TRIOC) | completed | Phase 2 | 94 | University College, LondonOTHER | 1 | May 9, 2019 | clinicaltrials |
| NCT03573011 | PSMA PET/CT for Prostate Cancer(NGP2) | completed | Phase 2 | 64 | University Hospital, GhentOTHER | 1 | May 6, 2019 | clinicaltrials |
| NCT00528866 | Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy | completed | Phase 2 | 80 | Radiation Therapy Oncology GroupNETWORK | 2 | Apr 24, 2019 | clinicaltrials |
| NCT01230996 | Dose Escalation Study of Simultaneous Boost Intensity-Modulated Radiotherapy for Locally Advanced Cervical Cancer(DEPICT) | completed | Phase 1 / Phase 2 | 22 | Barts & The London NHS TrustOTHER | 1 | Apr 24, 2019 | clinicaltrials |
| NCT00088413 | PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer | completed | Phase 1 / Phase 2 | 51 | National Cancer Institute (NCI)NIH | 1 | Apr 16, 2019 | clinicaltrials |
| NCT00348595 | Study of 2 Different Doses of Revlimid in Biochemically Relapse Prostate Cancer | completed | Phase 1 / Phase 2 | 77 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 12, 2019 | clinicaltrials |
| NCT03081481 | Intraprostatic PRX302 Injection to Treat Localised Prostate Cancer | completed | Phase 2 | 38 | Sophiris Bio CorpINDUSTRY | 2 | Apr 10, 2019 | clinicaltrials |
| NCT00642018 | A Study of an Experimental Chemotherapy Combination to Treat Hormone Refractory Prostate Cancer | completed | Phase 2 | 154 | Eli Lilly and CompanyINDUSTRY | 4 | Apr 3, 2019 | clinicaltrials |
| NCT00274287 | GM-CSF for Maintenance of Prostate Cancer for Patients Responding to Taxotere | completed | Phase 2 | 15 | Oncology Specialists, S.C.OTHER | 1 | Mar 28, 2019 | clinicaltrials |
| NCT00407758 | Enzastaurin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer | completed | Phase 2 | 28 | Gynecologic Oncology GroupNETWORK | 1 | Mar 20, 2019 | clinicaltrials |
| NCT01267253 | Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer | completed | Phase 2 | 31 | Gynecologic Oncology GroupNETWORK | 1 | Mar 20, 2019 | clinicaltrials |
| NCT01927627 | Enzalutamide in Patients With High-risk Prostate Cancer | completed | Phase 2 | 42 | Case Comprehensive Cancer CenterOTHER | 1 | Mar 20, 2019 | clinicaltrials |
| NCT01487863 | Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer | completed | Phase 2 | 69 | DendreonINDUSTRY | 1 | Mar 19, 2019 | clinicaltrials |
| NCT01685983 | A Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate Cancer | completed | Phase 2 | 82 | Janssen Research & Development, LLCINDUSTRY | 2 | Mar 15, 2019 | clinicaltrials |
| NCT01304485 | PET Imaging Characteristics of C11-Acetate in Patients With Recurrent Prostate Carcinoma | completed | Phase 2 | 2,000 | Phoenix Molecular ImagingOTHER | 1 | Mar 7, 2019 | clinicaltrials |
| NCT01530269 | C11-Sodium Acetate PET/CT Imaging for Metastatic Disease in Intermediate-to-high Risk Prostate Adenocarcinoma | completed | Phase 2 | 300 | Phoenix Molecular ImagingOTHER | 1 | Mar 7, 2019 | clinicaltrials |
| NCT02128126 | Study of the Therapeutic Vaccine (ISA101/ISA101b) to Treat Advanced or Recurrent Cervical Cancer(CervISA) | completed | Phase 1 / Phase 2 | 93 | ISA PharmaceuticalsINDUSTRY | 3 | Mar 6, 2019 | clinicaltrials |
| NCT01381861 | Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma | completed | Phase 2 | 23 | Tracon Pharmaceuticals Inc.INDUSTRY | 1 | Mar 5, 2019 | clinicaltrials |
| NCT01553188 | AMG 386 and Abiraterone for Advanced Prostate Cancer | completed | Phase 2 | 36 | National Cancer Institute (NCI)NIH | 1 | Mar 5, 2019 | clinicaltrials |
| NCT01677897 | Impact of the Addition of Metformin to Abiraterone in Metastatic Prostate Cancer Patients(MetAb-Pro) | completed | Phase 2 | 25 | Kantonsspital GraubündenOTHER | 1 | Mar 5, 2019 | clinicaltrials |
| NCT00331760 | Intensity-Modulated Radiation Therapy to the Pelvis With or Without Chemotherapy in Treating Patients With Endometrial Cancer or Cervical Cancer That Has Been Removed By Surgery | completed | Phase 2 | 106 | Radiation Therapy Oncology GroupNETWORK | 2 | Feb 26, 2019 | clinicaltrials |
| NCT00436501 | VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | completed | Phase 1 / Phase 2 | 58 | National Cancer Institute (NCI)NIH | 1 | Feb 26, 2019 | clinicaltrials |
| NCT00570700 | Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer | completed | Phase 2 | 38 | University of California, IrvineOTHER | 1 | Feb 26, 2019 | clinicaltrials |
| NCT00311623 | Sirolimus Before Surgery in Treating Patients With Advanced Localized Prostate Cancer | completed | Phase 1 / Phase 2 | 32 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 22, 2019 | clinicaltrials |
| NCT00480090 | A Phase II Study of Ara-C (Cytarabine) in Men With Androgen Independent Prostate Cancer(SLAP) | completed | Phase 2 | 10 | University Health Network, TorontoOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT01120470 | OGX-427 in Castration Resistant Prostate Cancer Patients | completed | Phase 2 | 74 | British Columbia Cancer AgencyOTHER | 2 | Feb 15, 2019 | clinicaltrials |
| NCT02507427 | Monitoring and Mapping of Erectile Nerve During RALP (MMEN Study) | completed | Phase 1 / Phase 2 | 30 | Seoul National University HospitalOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT03001895 | Correlation Between SUV on 18F-DCFPyL PET/CT and Gleason Score in Prostate Cancer | completed | Phase 2 | 120 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT00022399 | Celecoxib Compared With No Treatment Before Surgery in Treating Patients With Localized Prostate Cancer | completed | Phase 2 | 73 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 8, 2019 | clinicaltrials |
| NCT01257425 | Equivalence of Intramuscular (IM) Versus Subcutaneous (SC) Applications of Long Acting Pamorelin 11.25 mg(PAMIS) | completed | Phase 2 | 109 | IpsenINDUSTRY | 1 | Feb 8, 2019 | clinicaltrials |
| NCT02012920 | A Study to Evaluate Oral VT-464 in Patients With Castration-Resistant Prostate Cancer | completed | Phase 2 | 200 | Innocrin PharmaceuticalINDUSTRY | 4 | Feb 1, 2019 | clinicaltrials |
Data updated 24 days agoSource updated Jul 9, 2019source: clinicaltrials